Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler

NCT: NCT05620043 · COMPLETED

NCT IDNCT05620043
StatusCOMPLETED
Start Date2022-09-28
Completion2023-11-06

Brief Summary

To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy

Frequently Asked Questions

What is Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler?

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler is a clinical trial registered under NCT05620043. Current status: COMPLETED.

What is the status of NCT05620043?

The current status of NCT05620043 (Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler) is: COMPLETED.

When did Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler start?

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler started on 2022-09-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑